Clinical Trials in Danbury, Connecticut

36 recruiting

Showing 120 of 34 trials

Recruiting
Phase 2Phase 3

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease
Janssen Research & Development, LLC1,092 enrolled358 locationsNCT07196722
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled233 locationsNCT07061977
Recruiting
Phase 3

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled836 locationsNCT05812807
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled385 locationsNCT07196748
Recruiting
Phase 3

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

Atrial FibrillationIntracerebral Hemorrhage
Yale University700 enrolled187 locationsNCT03907046
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 3

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Breast Cancer
NRG Oncology3,960 enrolled1238 locationsNCT05879926
Recruiting
Not Applicable

Assessment of CCM in HF With Higher Ejection Fraction

Heart FailureHeart Failure With Preserved Ejection FractionDiastolic Heart Failure+2 more
Impulse Dynamics1,500 enrolled105 locationsNCT05064709
Recruiting
Phase 2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled141 locationsNCT06157892
Recruiting

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

Malignant Solid Neoplasm
SWOG Cancer Research Network2,062 enrolled849 locationsNCT04871542
Recruiting

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 3

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

Diabetic Macular Edema (DME)Diabetic Macular EdemaDME
EyePoint Pharmaceuticals, Inc.240 enrolled48 locationsNCT07449923
Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled339 locationsNCT05633654
Recruiting
Phase 3

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+1 more
NRG Oncology356 enrolled279 locationsNCT06958328
Recruiting
Phase 3

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Breast Cancer
Canadian Cancer Trials Group2,140 enrolled483 locationsNCT03488693
Recruiting
Phase 3

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Cardiovascular RiskAcute Myocardial Infarction (AMI)
Novo Nordisk A/S10,000 enrolled970 locationsNCT06118281
Recruiting
Phase 3

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

Ischemic Stroke; Ischemic Attack, Transient
Janssen Research & Development, LLC15,000 enrolled880 locationsNCT05702034
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting
Phase 2

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Crohn's Disease
AbbVie540 enrolled254 locationsNCT06548542
Recruiting
Phase 3

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Ovarian CarcinomaOvarian High Grade Serous AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+6 more
NRG Oncology880 enrolled676 locationsNCT06580314